SAFETY PROFILES OF IXEKIZUMAB VERSUS ADALIMUMAB: 52-WEEK RESULTS FROM A HEAD-TO-HEAD COMPARISON IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

被引：0
|
作者：
Mease, P. J. [1 ]
Smolen, J. S. [2 ]
Kavanaugh, A. [3 ]
Nash, P. [4 ]
Gallo, G. [5 ]
Leage, S. Liu [5 ]
Sapin, C. [5 ]
Genovese, M. C. [6 ]
机构：
[1] Seattle Rheumatol Associates PLLC, Seattle, WA USA
[2] Med Univ Vienna, Vienna, Austria
[3] UC San Diego Hlth Syst, San Diego, CA USA
[4] Griffith Univ, Sch Med, Brisbane, Qld, Australia
[5] Eli Lilly & Co, Corp Ctr, Indianapolis, IN 46285 USA
[6] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.1365
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0802
引用
收藏
页码：1698 / 1698
页数：1
相关论文
共 50 条
  • [41] Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naive Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
    Smolen, Josef S.
    Sebba, Anthony
    Ruderman, Eric M.
    Schulze-Koops, Hendrik
    Sapin, Christophe
    Gellett, Amanda M.
    Sprabery, Aubrey Trevelin
    Li, Lingnan
    de la Torre, Inmaculada
    Gallo, Gaia
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Reis, Paulo
    Nash, Peter
    RHEUMATOLOGY AND THERAPY, 2020, 7 (04) : 1021 - 1035
  • [42] HEAD-TO-HEAD STUDY EVALUATING THE COMBINED ACR50/PASI100 TREATMENT RESPONSE OF IXEKIZUMAB VERSUS ADALIMUMAB: INDIVIDUAL PATIENT DATA FROM A RANDOMIZED, OPEN-LABEL STUDY IN BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS THROUGH WEEK 52
    Kavanaugh, A.
    Lubrano, E.
    Muram, T.
    Lin, C. Y.
    Leage, S. Liu
    Van den Bosch, F.
    Kristensen, L. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 763 - 763
  • [43] Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
    Schiff, Michael
    Weinblatt, Michael E.
    Valente, Robert
    van der Heijde, Desiree
    Citera, Gustavo
    Elegbe, Ayanbola
    Maldonado, Michael
    Fleischmann, Roy
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 86 - 94
  • [44] EFFICACY AND SAFETY OF IXEKIZUMAB AT WEEK 52 IN BIOLOGIC NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (SPIRIT-P1)
    Lespessailles, Eric
    Kirkham, Bruce
    Nebro, Antonio Fernandez
    Blanco, Ricardo
    Strehblow, Christoph
    Inciarte-Mundo, Jose
    Porsdal, Vibeke
    Garcia, Miriam
    Kurzawa, Monika
    Sapin, Christophe
    Geusens, Piet
    Goupille, Philippe
    Tahir, Hasan
    RHEUMATOLOGY, 2018, 57
  • [45] Head-to-Head Comparison of Subcutaneous Abatacept Versus Adalimumab in the Treatment of Rheumatoid Arthritis: Key Efficacy and Safety Results from the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
    Maldonado, Michael
    Weinblatt, Michael
    Schiff, Michael
    Fleischmann, Roy
    Valente, Robert
    Van der Heijde, Desiree
    Citera, Gustavo
    Zhao, Cathy
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 1005 - 1006
  • [46] Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
    Josef S. Smolen
    Anthony Sebba
    Eric M. Ruderman
    Hendrik Schulze-Koops
    Christophe Sapin
    Amanda M. Gellett
    Aubrey Trevelin Sprabery
    Lingnan Li
    Inmaculada de la Torre
    Gaia Gallo
    Soyi Liu-Leage
    Sreekumar Pillai
    Paulo Reis
    Peter Nash
    Rheumatology and Therapy, 2020, 7 : 1021 - 1035
  • [47] Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies
    McInnes, Iain B.
    Mease, Philip J.
    Tanaka, Yoshiya
    Gossec, Laure
    Husni, M. Elaine
    Kristensen, Lars Erik
    Warren, Richard B.
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Gottlieb, Alice B.
    ACR OPEN RHEUMATOLOGY, 2024, 6 (11) : 720 - 731
  • [48] Efficacy and safety of ixekizumab at week 24 in biologic-experienced patients with active psoriatic arthritis: summary results
    Marzo-Ortega, H.
    Meroni, P.
    Galindez-Agirregoikoa, E.
    Behrens, F.
    Bradley, A.
    Leage, S. Liu
    Garcia, M.
    Sapin, C.
    Ho, J.
    Constantin, A.
    Hall, S.
    Porsdal, V.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 : 43 - 44
  • [49] Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study
    Fleischmann, Roy
    Burmester, Gerd-Rudiger
    Combe, Bernard
    Curtis, Jeffrey R.
    Hal, Stephen
    Haraoui, Boulos
    van Vollenhoven, Ronald
    Cioffi, Christopher
    Ecoffet, Cecile
    Ionescu, Lucian
    Gervitz, Leon
    Peterson, Luke
    Smolen, Josef
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [50] Efficacy and safety of ixekizumab at week 52 in biologic-naive patients with active psoriatic arthritis (SPIRIT-P1)
    Lespessailles, E.
    Kirkham, B.
    Nebro, A.
    Alonso, R.
    Strehblow, C.
    Inciarte, J.
    Porsdal, V.
    Garcia, M.
    Kurzawa, M.
    Sapin, C.
    Geusens, P.
    Goupille, P.
    Tahir, H.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 : 44 - 45
12345